297 related articles for article (PubMed ID: 29491296)
1. Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy.
Nawata T; Kubo M; Fujii S; Shiragami K; Ikegami T; Kobayashi S; Hisano S; Yano M
Intern Med; 2018 Jul; 57(14):2067-2070. PubMed ID: 29491296
[TBL] [Abstract][Full Text] [Related]
2. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil].
Suszek D; Wielosz E; Majdan M
Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951
[TBL] [Abstract][Full Text] [Related]
3. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
[TBL] [Abstract][Full Text] [Related]
4. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
[TBL] [Abstract][Full Text] [Related]
5. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?
Hogan J; Schwenk MH; Radhakrishnan J
Kidney Int; 2012 Dec; 82(12):1256-60. PubMed ID: 22648298
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
Fu YF; Liu GL
Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
[TBL] [Abstract][Full Text] [Related]
8. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
9. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan.
Yasuda S; Atsumi T; Shimamura S; Ono K; Hiromura K; Sada K; Mori M; Takei S; Kawaguchi Y; Tamura N; Takasaki Y
Mod Rheumatol; 2015; 25(6):854-7. PubMed ID: 25800636
[TBL] [Abstract][Full Text] [Related]
11. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
12. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
[TBL] [Abstract][Full Text] [Related]
14. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil in lupus nephritis.
Ginzler EM; Aranow C
Lupus; 2005; 14(1):59-64. PubMed ID: 15732290
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
Fließer EE; Korsten P; Koziolek MJ; Niewold TB; Patschan D; Müller GA; Patschan SA
Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
[TBL] [Abstract][Full Text] [Related]
18. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
19. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
Rovin BH; Parikh SV; Hebert LA; Chan TM; Mok CC; Ginzler EM; Hooi LS; Brunetta P; Maciuca R; Solomons N
Clin J Am Soc Nephrol; 2013 Jan; 8(1):147-53. PubMed ID: 22879439
[TBL] [Abstract][Full Text] [Related]
20. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.
Katsuno T; Ozaki T; Ozeki T; Hachiya A; Kim H; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Mizuno M; Ito Y; Maruyama S
Clin Exp Nephrol; 2018 Dec; 22(6):1341-1350. PubMed ID: 29796823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
